Evolution of the Average Target: Axsome Therapeutics, Inc.

Evolution of the Target Price: Axsome Therapeutics, Inc.

Changes in Analyst Recommendations: Axsome Therapeutics, Inc.

866bb6a10.yOMZijrQL0GWUXSnXRlx9KptY_KGMYCQ1sqeNY-4cxc.hZAqvH68GTHcfCHDBHNEs80kEt_Sfa2nko3tYPr6AG6LryrLaeFcGaMbQA~73de531b8ea0b9f565a35368ab1165e2
09-25 Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says MT
09-23 Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating MT
09-18 Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says MT
09-01 Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says MT
08-12 UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating MT
08-12 Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating MT
08-11 Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says MT
08-11 Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating MT
08-11 RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating MT
07-31 Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating MT
07-21 BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target MT
07-07 RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating MT
05-27 Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says MT
05-05 B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating MT
05-05 Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating MT
05-05 RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating MT
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
05-04 Deutsche Bank Adjusts Axsome Therapeutics PT to $281 From $245, Maintains Buy Rating MT
04-29 Mizuho Keeps Price Target on Axsome Therapeutics to $228, Maintains Outperform Rating MT
04-29 Mizuho Adjusts Price Target on Axsome Therapeutics to $228 From $230, Maintains Outperform Rating MT
04-28 Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating MT
04-21 Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says MT
04-10 Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says MT
04-10 UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating MT
04-07 RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+46.2%
+7.97%
-39.89%
+1.62%
+44.41%
+32.93%
+4.65%
+3.11%
+29.52%
+14.84%
Average +14.54%
Weighted average by Cap. +6.58%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
195.09USD
Average target price
285.22USD
Spread / Average Target
+46.20%
High Price Target
380.00USD
Spread / Highest target
+94.78%
Low Price Target
246.00USD
Spread / Lowest Target
+26.10%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. AXSM Stock
  4. Consensus Axsome Therapeutics, Inc.